Novartis re-launches patient education program

Share this article:
Novartis has embarked "on a mission" to fight hypertension while backing its best-selling product, the blood-pressure-lowering medication Diovan, according to the drugmaker's top financial official.
"We are on a mission in hypertension because we think there is a lot of unmet [patient] need," said Novartis chief operating officer Alex Gorsky speaking at Bear Stearns' annual healthcare conference in New York.
To help achieve its goal of "lowering America's blood pressure," Novartis rebranded and reformatted its Take Action for Healthy BP patient education program as the BP Success Zone. The renamed program, featuring a new compliance component, was launched in July.
BP Success Zone helps patients by providing medication, a free Omron blood pressure monitor with rebate, customized patient education that features lifestyle modification action plans, and a members' Web site with blood pressure tracking tools.
The new compliance component to the program helps promote smoking cessation, a low salt diet, exercise, weight reduction and stress reduction.
Diovan is Novartis' top-selling product, with global sales in the 12 months to June 2005 topping the $1.7 billion dollar mark, according to company figures.
Share this article:
close

Next Article in News

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZeneca beefs up respiratory portfolio

AstraZeneca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.